# A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma

> **NCT05169515** · PHASE1 · RECRUITING · sponsor: **Hoffmann-La Roche** · enrollment: 121 (estimated)

## Conditions studied

- Non-Hodgkin Lymphoma

## Interventions

- **DRUG:** SC Mosunetuzumab
- **DRUG:** IV Glofitamab
- **DRUG:** Iberdomide
- **DRUG:** Golcadomide
- **DRUG:** Obinutuzumab
- **DRUG:** Tocilizumab

## Key facts

- **NCT ID:** NCT05169515
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-10-26
- **Primary completion:** 2029-09-15
- **Final completion:** 2029-09-15
- **Target enrollment:** 121 (ESTIMATED)
- **Last updated:** 2026-05-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05169515

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05169515, "A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma". Retrieved via AI Analytics 2026-09-01 from https://api.ai-analytics.org/clinical/NCT05169515. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*